Europe’s Huge Breakthrough in Access to Psychedelic Therapies

Psychedelic therapy access is expanding in Europe, with Germany’s first compassionate use program for psilocybin therapies for treatment-resistant depression marking a major milestone. The article highlights Dr. Gerhard Gründer’s EPIsoDE study results from psilocybin-assisted therapy in 144 patients with treatment-resistant depression, and describes how that evidence helped Germany’s Federal Institute for Drugs and Medical Devices authorize psilocybin for exceptional adult cases at two medical facilities under strict criteria. It also notes demand pressures, limited first-year capacity, and the plan to expand sites. Beyond Germany, the piece covers Europe-wide policy momentum, including Switzerland’s earlier framework for therapeutic use reporting, UK regulatory reform to ease research on Schedule 1 drugs, and a Czech Republic law expected to take effect in 2026 that would allow physicians to administer psilocybin within psychedelic-assisted psychotherapy for specified conditions. The article frames these steps as a path toward collecting real-world patient outcome data and shaping future regulation and broader, safer clinical care.